Angiotech Vascular Wrap Will Bring Paclitaxel To Vascular Surgeons
This article was originally published in The Gray Sheet
Executive Summary
Angiotech will begin clinical trials in late 2003 on its paclitaxel-eluting Vascular Wrap for prevention of restenosis following leg artery bypass surgery
You may also be interested in...
Angiotech Vascular Wrap
European trial begins study of 60 patients implanted with paclitaxel-eluting wrap for surgical bypass of femoral-popliteal arterial disease. The device is designed to prevent restenosis at the bypass graft anastamosis site from the outside of the vessel in a process similar to the anti-restenotic action of drug-eluting stents. Angiotech is targeting a 2005 U.S. approval of the Vascular Wrap, which will be marketed by C.R. Bard (1"The Gray Sheet, Jan 13, 2003, p. 29)...
Angiotech Vascular Wrap
European trial begins study of 60 patients implanted with paclitaxel-eluting wrap for surgical bypass of femoral-popliteal arterial disease. The device is designed to prevent restenosis at the bypass graft anastamosis site from the outside of the vessel in a process similar to the anti-restenotic action of drug-eluting stents. Angiotech is targeting a 2005 U.S. approval of the Vascular Wrap, which will be marketed by C.R. Bard (1"The Gray Sheet, Jan 13, 2003, p. 29)...
Angiotech On Track To Building Drug-Loaded Device Franchise – CEO Hunter
Angiotech's combination product pipeline includes drug-loaded versions of the CoSeal surgical sealant, CoStasis surgical hemostat and Adhibit adhesion barrier, CEO William Hunter stated in an Aug. 17 earnings call